Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

Creative Commons License

BÜYÜKAŞIK Y.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.21, sa.2, ss.4-9, 2011 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.4999/uhod.11012
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.4-9
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.